drugset / Trial / NCT05630183
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer. One group of participants will only receive chemotherapy while a second group of participants will receive botensilimab and chemotherapy.
Timeline
- Start
- 2023-03-27
- Primary completion
- 2026-01-05
- Completion
- 2026-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botensilimab | Monoclonal antibody | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |